May 2021 saw a shift in the balance of power in India’s hospital supply chain segment. Bengaluru-based Akna Medical acquired specialty drugs distributor Vardhman Health on 19 May, becoming India’s largest hospital supplier in the process.

It’s a big leap for the young startup, which was only founded in November 2018. In the year ended March 2020,  Aknamed, as the brand is called, earned Rs 24 crore ($3.3 million) in revenue. That same year, Vardhman—which was founded in 1997—clocked revenues of Rs 373 crore ($50.8 million). The $35 million acquisition is Aknamed’s third and most expensive acquisition of a drug distributor in its short lifetime. Last year, it bought Delhi-based Impex Healthcare and Mumbai-based Shreeji Distributors Pharma, which together accounted for revenues of over Rs 100 crore ($13.6 million) for the financial year ended March 2020. Aknamed declined to reveal how much it spent on both companies. 

The juice for Aknamed’s acquisitions came from a Series B round of about $50 million that it is still in the process of raising, according to an executive who is aware of Aknamed’s plans. They requested anonymity as the company is yet to announce this fundraise. Previously, Aknamed raised Rs 54 crore ($7.4 million) in a Series A round from Bengaluru-based private equity (PE) fund LGT Lightstone Aspada, now known as Lightrock, in April 2020.

These three acquisitions have fleshed out Aknamed’s offerings. Originally, the startup built a basket of products ranging from drugs used by pediatric, obstetrics, and gynaecology departments, and medical products ranging from diapers to stents. With Impex, it gained access to specialty drugs such as immunotherapy and critical care—including remdesivir that was approved for the treatment of Covid-19—in Delhi. Shreeji gave it the generics medicines market in Mumbai. Vardhman, the latest piece in the Aknamed puzzle, added a countrywide oncology portfolio to Aknamed’s basket.

With the three acquisitions, Aknamed now has a client list of over 750 hospitals across the country. It now stands primed to spread its roots further afield in India’s hospital supply chain segment. Accounting for a quarter of the overall Indian healthcare industry—a market forecast to reach Rs 8,60,000 crore (US$ 132.84 billion) by March 2022—the hospital supply segment is worth an estimated Rs 2,15,000 crore ($29.3 billion). 

With its product basket now overflowing, Aknamed plans to halt its acquisition spree, said Saurabh Pandey, the company’s co-founder and CEO. 

Pandey now plans to integrate the acquired businesses to hit a target revenue of Rs 5,000 crore ($681 million) over the next four years as Aknamed attempts to become a one-stop-shop for everything that a hospital needs to operate.

The Team

Aknamed was founded by Saurabh Pandey and Mahadevan Narayanamoni in 2018.

AUTHOR

Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.